# A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

> **NCT03454620** · PHASE1,PHASE2 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 53 (actual)

## Conditions studied

- Metastatic Colorectal Cancer
- Solid Tumor

## Interventions

- **DRUG:** irinotecan
- **DRUG:** FOLFIRI

## Key facts

- **NCT ID:** NCT03454620
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-02
- **Primary completion:** 2021-09-17
- **Final completion:** 2022-01-10
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2022-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03454620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03454620, "A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03454620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*